<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="104291">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02027961</url>
  </required_header>
  <id_info>
    <org_study_id>CD-ON-MEDI4736-1161</org_study_id>
    <nct_id>NCT02027961</nct_id>
  </id_info>
  <brief_title>Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone</brief_title>
  <official_title>A Phase 1 Open-label Study of Safety and Tolerability of MEDI4736 in Subjects With Metastatic or Unresectable Melanoma in Combination With Dabrafenib and Trametinib or With Trametinib Alone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <authority>European Union: European Medicines Agency</authority>
    <authority>Canada: Health Canada</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the maximum tolerated dose and the safety profile
      of MEDI4736 in combination with dabrafenib and trametinib or with trametinib alone in
      subjects with metastatic or unresectable melanoma with BRAF-mutation positive or Wild Type
      BRAF, respectively.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Maximum Tolerated Dose/Safety</measure>
    <time_frame>90 days after the last dose of MEDI4736</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The primary endpoint for determining maximum tolerated dose includes dose limiting toxicities. The primary endpoint for safety assessment include adverse events, serious adverse events, laboratory evaluations, vitial signs, physical examination, and echocardiogram/elecrocardiogram results.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antitumor Activity</measure>
    <time_frame>90 days after the last dose of investigational product</time_frame>
    <safety_issue>No</safety_issue>
    <description>The endpoints for assessment of antitumor activity include objective response based on revised RECIST criteria Version 1.1, duration of response, progression-free survival, and overall survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor Activity</measure>
    <time_frame>90 days after the last dose of investigational product</time_frame>
    <safety_issue>No</safety_issue>
    <description>The endpoints for assessment of antitumor activity include disease control, based on revised RECIST criteria Version 1.1, duration of response, progression-free survival, and overall survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic of MEDI4736</measure>
    <time_frame>90 days after the last dose of MEDI4736</time_frame>
    <safety_issue>No</safety_issue>
    <description>PK of MEDI4736 includes individual MEDI4736 concentrations in serum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic of MEDI4736</measure>
    <time_frame>90 days after the last dose of MEDI4736</time_frame>
    <safety_issue>No</safety_issue>
    <description>PK parameters of MEDI4736 including peak concentration, area under the concentration-time curve clearance and half-life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of MEDI4736</measure>
    <time_frame>90 days after the last dose of MEDI4736</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Immunogenicity of MEDI4736 include the number and percentage of subjects who develop detectable anti-drug antibodies.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">69</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dabrafenib/Trametinib/MEDI4736</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trametinib/MEDI4736</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trametinib/MEDI4736</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI4736</intervention_name>
    <description>MEDI4736</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_label>Cohort C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabrafenib</intervention_name>
    <description>Dabrafenib</description>
    <arm_group_label>Cohort A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trametinib</intervention_name>
    <description>Trametinib</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_label>Cohort C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults &gt;/= 18 years old

          -  Histologically confirmed cutaneous melanoma that is either Stage IIIc (unresectable)
             or Stage IV (metastatic) and determined to be BRAF V600E or V600K mutation-positive
             (cohort A) or mutation-negative (cohorts B and C)

          -  ECOG performance status of 0 or 1

          -  Measurable disease by radiographic or physical examination

          -  Adequate organ and marrow function

          -  Willingness to provide consent for biopsies positive or BRAF WT measurable disease,
             Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and adequate
             organ and marrow function

        Exclusion Criteria:

          -  Prior treatment with a BRAF inhibitor or MEK inhibitor

          -  Any prior Grade ≥ 3 immune-related adverse event while receiving immunotherapy

          -  Active or prior documented autoimmune disease within the past 2 years

          -  History of or current risk for retinal vein occlusion (RVO) or central serous
             retinopathy (CSR)

          -  History of or current cardiovascular risk including myocardial infarction, ≥ Class II
             congestive heart failure,  uncontrolled arrhythmias, or refractory hypertension

          -  Active, untreated CNS metastases

          -  Women who are pregnant or lactating
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andy Blake-Haskins, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shaista Parveen</last_name>
    <email>ClinicalTrialEnquiries@Medimmune.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sherry Warwick</last_name>
    <email>clinicaltrialenquiries@medimmune.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 23, 2014</lastchanged_date>
  <firstreceived_date>November 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic or Unresectable Melanoma, MEDI4736, dafrafenib, trametinib, BRAF-mutation positive, wild-type BRAF, PD-L1, PD-1</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
